Novartis Ag NVS
NYSE NVS
$161.75 -3.23 (-1.96%)
As of: Nov 5, 2026 · 3:59 PM EST

Novartis Ag (NVS) Income from Continuing Operations (2009 - 2026)

Updated

Novartis Ag's Income from Continuing Operations was $3.26 billion in Q2 2026, down 19.1% from $4.02 billion a year earlier and down 28.0% from the prior quarter.

Analysis

Novartis Ag (NVS) Income from Continuing Operations (2009 - 2026) Analysis & Trends

On a trailing twelve-month basis, Novartis Ag's Income from Continuing Operations was $16.27 billion through Jun 30, 2026, up 6.8% year-over-year; for FY2025, it came in at $13.97 billion, up 17.0% from FY2024.

  • Income from Continuing Operations shows a five-year compound annual growth rate of 11.6% (FY2020 to FY2025).
  • In earlier years, Income from Continuing Operations was $11.94 billion in FY2024 (-4.9%), $12.55 billion in FY2023 (+12.6%), $11.15 billion in FY2022 (-51.3%) and $22.91 billion in FY2021 (+183.8%).
  • The Q2 2026 figure marks the lowest quarterly Income from Continuing Operations since Q4 2024.
  • Compared with a year earlier, Income from Continuing Operations was higher in six of the last eight quarters, with growth averaging 35.7%.
  • The best year-over-year quarter for Income from Continuing Operations over five years was Q4 2021 (growth of 738.3%); the worst was Q4 2022 (a decline of 92.5%).
  • Per Business Quant data, NVS's Income from Continuing Operations in the three quarters before Q2 2026 was $4.52 billion (Q1 2026), $4.03 billion (Q4 2025) and $4.46 billion (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Eli Lilly 1,221.09 Bn 1,194.71 Bn 20.46 Bn 6.45 Bn
2 Johnson & Johnson 656.38 Bn 576.24 Bn 17.30 Bn 210.00 Mn
3 AbbVie 510.79 Bn 478.80 Bn 13.12 Bn 4.22 Bn
4 Merck 363.00 Bn 317.38 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 313.89 Bn 287.12 Bn - -
6 Astrazeneca 290.02 Bn 263.91 Bn 13.26 Bn 4.80 Bn
7 Amgen 249.59 Bn 204.98 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 208.15 Bn 183.26 Bn 6.73 Bn 2.43 Bn
9 Pfizer 170.74 Bn 118.10 Bn 12.56 Bn 3.25 Bn
10 Vertex Pharmaceuticals 137.20 Bn 109.19 Bn 2.91 Bn 653.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.26 Bn
Mar 31, 2026 4.52 Bn
Dec 31, 2025 4.03 Bn
Sep 30, 2025 4.46 Bn
Jun 30, 2025 4.02 Bn
Mar 31, 2025 5.21 Bn
Dec 31, 2024 2.82 Bn
Sep 30, 2024 3.19 Bn
Jun 30, 2024 3.25 Bn
Mar 31, 2024 2.69 Bn
Dec 31, 2023 2.64 Bn
Sep 30, 2023 1.51 Bn
Jun 30, 2023 2.27 Bn
Mar 31, 2023 2.15 Bn
Dec 31, 2022 1.32 Bn
Sep 30, 2022 1.33 Bn
Jun 30, 2022 1.70 Bn
Mar 31, 2022 3.12 Bn
Dec 31, 2021 17.60 Bn
Sep 30, 2021 3.70 Bn
API Access

Novartis Ag Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=NVS&period=max&api_key=YOUR_API_KEY